Today, a brief rundown of news from Merck & Co. and Roche, as well as updates from Sangamo Therapeutics, UCB and Catalent that you may have missed.

今天，简要介绍一下默克公司（Merck＆Co.）和罗氏公司（Roche）的新闻，以及Sangamo Therapeutics、UCB和Catalent的最新消息，您可能错过了。

Merck & Co. will pay $30 million upfront to acquire Modifi Biosciences, a Yale University spinout developing small molecule drugs for cancer. Founded in 2021, Modifi focuses on DNA repair defects in cancer cells, specifically one repair protein known as MGMT for short. Shareholders in Modifi could receive up to $1.3 billion in additional payments if certain, unspecified milestones are met.

默克公司（Merck＆Co.）将预付3000万美元收购Modifi Biosciences，这是耶鲁大学（Yale University）推出的一项针对癌症的小分子药物开发项目。Modifi成立于2021年，专注于癌细胞中的DNA修复缺陷，特别是一种修复蛋白，简称MGMT。如果达到某些未明确的里程碑，Modifi的股东可能会获得多达13亿美元的额外付款。

— Ned Pagliarulo.

内德·帕格里亚鲁洛。

Sales of Sarepta Therapeutics’ Duchenne muscular dystrophy gene therapy Elevidys outside of the U.S. reached 137 million Swiss francs, or about $156 million, over the first nine months of the year, the company’s international partner Roche said Wednesday. Those sales came from five ex-U.S. countries where Elevidys is also approved.

Sarepta Therapeutics的国际合作伙伴Roche周三表示，今年前9个月，Sarepta Therapeutics的Duchenne肌营养不良基因治疗Elevidys在美国境外的销售额达到1.37亿瑞士法郎，约合1.56亿美元。这些销售来自Elevidys也获得批准的五个前美国国家。

A decision is expected in the EU next year, and Roche has submitted applications in several other countries. The Swiss group cited Elevidys, along with multiple sclerosis shot Ocrevus, as one of its key growth drivers in neurology, which showed a sales increase of 14% to 7 billion francs over the same period in 2023.

预计明年欧盟将作出决定，罗氏已在其他几个国家提交了申请。这家瑞士集团将Elevidys和多发性硬化症疫苗Ocrevus列为其神经病学领域的主要增长驱动因素之一，2023年同期销售额增长14%，达到70亿法郎。

— Jonathan Gardner.

-。

Shares in Sangamo Therapeutics rose Tuesday after the company said it has secured agreement from the Food and Drug Administration on a path to filing its experimental Fabry disease treatment for approval. According to the biotechnology company, regulators agreed that a measure of kidney function could be used as a surrogate endpoint to ask it for accelerated clearance of the gene therapy, dubbed isaralgagene civaparvovec or ST-920.

桑加莫治疗公司（Sangamo Therapeutics）股价周二上涨，此前该公司表示已获得美国食品和药物管理局（Food and Drug Administration）的同意，同意将其实验性法布里病治疗方案提交批准。据该生物技术公司称，监管机构同意将肾功能指标作为替代终点，要求其加速清除基因治疗，称为isaralgagene civaparvovec或ST-920。

Sangamo expects to have the necessary data by the first half of next year, setting up a submission in the latter half of 2025 — some three years earlier than the company had been planning. — Ned Pagliarulo.

Sangamo预计将在明年上半年获得必要的数据，并在2025年下半年提交，比公司计划的时间早了大约三年内德·帕利亚鲁洛。

Roche has returned to UCB rights to an experimental Alzheimer’s medicine UCB had licensed to the Swiss pharmaceutical company in 2020. The company confirmed Roche’s termination of the collaboration in a statement Tuesday announcing the planned presentation of Phase 2 study results for the drug, bepranemab, at an upcoming medical meeting.

罗氏（Roche）已将加州大学伯克利分校（UCB）于2020年向瑞士制药公司（Swiss pharmaceutical company）许可的一种实验性阿尔茨海默病药物的权利归还给了加州大学伯克利分校（UCB）。该公司在周二的一份声明中证实了罗氏终止了合作，该声明宣布计划在即将举行的医学会议上介绍该药物bepranemab的第二阶段研究结果。

Tested in people with prodromal or mild Alzheimer’s, bepranemab is designed to target a protein known as tau in the brain. — Ned Pagliarulo.

在前驱或轻度阿尔茨海默氏病患者中进行测试，贝普拉尼单抗旨在靶向大脑中一种称为tau的蛋白质内德·帕利亚鲁洛。

MacroGenics, a developer of antibody medicines for cancer, on Tuesday said it sold rights to its breast cancer drug Margenza to privately held TerSera Therapeutics for $40 million. MacroGenics could receive up to $35 million more if certain sales milestones are met under the deal, which is expected to close in the fourth quarter.

癌症抗体药物开发商MacroGenics周二表示，它以4000万美元的价格将其乳腺癌药物Margenza的权利出售给了私人持有的TerSera Therapeutics。如果在该交易下达到某些销售里程碑，MacroGenics可能会获得高达3500万美元的额外收入，该交易预计将在第四季度完成。

Margenza was approved in 2020 together with chemotherapy for adults with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. — Delilah Alvarado.

Margenza于2020年被批准与化疗一起用于先前接受过两种或两种以上抗HER2方案的转移性HER2阳性乳腺癌患者黛利拉·阿尔瓦拉多。

Cell therapy developer AvenCell Therapeutics raised $112 million in a Series B financing led by investor Novo Holdings. The funding will fund development of the company’s “switchable” CAR-T medicines, which it claims could be safer and more effective than current options. F-Prime Capital, founding investor Blackstone Life Sciences and three other venture firms participated in the round.

细胞疗法开发商AvenCell Therapeutics在投资者Novo Holdings领导的B系列融资中筹集了1.12亿美元。这笔资金将用于开发该公司的“可转换”CAR-T药物，该公司声称这种药物可能比目前的选择更安全、更有效。F-Prime Capital、创始投资者Blackstone Life Sciences和其他三家风险投资公司参加了本轮投资。

— Delilah Alvarado.

-。

Catalent, the contract development and manufacturing organization being acquired by Novo Holdings, issued a letter Monday to its customers aimed at reassuring them it will continue to fulfill its commitments after the transaction closes. Novo Holdings, which is the parent company of drugmaker Novo Nordisk, is taking Catalent private through a $16.5 billion acquisition.

被Novo Holdings收购的合同开发和制造机构Catalent周一向其客户发出了一封信，旨在向他们保证，在交易结束后，它将继续履行其承诺。制药商诺和诺德（Novo Nordisk）的母公司诺和诺德控股（Novo Holdings）正以165亿美元收购Catalent private。

Novo Nordisk is then buying three large Catalent plants in a separate $11 billion agreement. Alessandro Maselli, Catalent’s current CEO, will stay on in his role, the letter said. — Ned Pagliarulo.

然后，诺和诺德将以110亿美元的单独协议收购三家大型Catalent工厂。信中说，加泰罗尼特现任首席执行官亚历山德罗·马塞利（AlessandroMaselli）将留任内德·帕利亚鲁洛。